SG11202111410SA - Pharmaceutical combination preparation comprising ezetimibe and losartan - Google Patents

Pharmaceutical combination preparation comprising ezetimibe and losartan

Info

Publication number
SG11202111410SA
SG11202111410SA SG11202111410SA SG11202111410SA SG11202111410SA SG 11202111410S A SG11202111410S A SG 11202111410SA SG 11202111410S A SG11202111410S A SG 11202111410SA SG 11202111410S A SG11202111410S A SG 11202111410SA SG 11202111410S A SG11202111410S A SG 11202111410SA
Authority
SG
Singapore
Prior art keywords
ezetimibe
losartan
pharmaceutical combination
combination preparation
preparation
Prior art date
Application number
SG11202111410SA
Inventor
Hyuk Jun Cho
Min Wook Kim
Ho Taek Im
Yong Il Kim
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of SG11202111410SA publication Critical patent/SG11202111410SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
SG11202111410SA 2019-04-18 2020-04-07 Pharmaceutical combination preparation comprising ezetimibe and losartan SG11202111410SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020190045295A KR102500643B1 (en) 2019-04-18 2019-04-18 Pharmaceutical combination preparation comprising ezetimibe and losartan
PCT/KR2020/004694 WO2020213868A1 (en) 2019-04-18 2020-04-07 Pharmaceutical combination preparation comprising ezetimibe and losartan

Publications (1)

Publication Number Publication Date
SG11202111410SA true SG11202111410SA (en) 2021-11-29

Family

ID=72838309

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202111410SA SG11202111410SA (en) 2019-04-18 2020-04-07 Pharmaceutical combination preparation comprising ezetimibe and losartan

Country Status (8)

Country Link
EP (1) EP3957303A4 (en)
KR (1) KR102500643B1 (en)
CN (1) CN113747885B (en)
MX (1) MX2021012568A (en)
SG (1) SG11202111410SA (en)
TW (1) TWI827828B (en)
WO (1) WO2020213868A1 (en)
ZA (1) ZA202108268B (en)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5138069A (en) 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
WO1995017396A1 (en) 1993-12-23 1995-06-29 Merck & Co., Inc. Polymorphs of losartan and the process for the preparation of form ii of losartan
CN101594850A (en) * 2006-12-21 2009-12-02 兰贝克赛实验室有限公司 Antilipidemic pharmaceutical compositions and and preparation method thereof
PT2120878E (en) * 2007-02-09 2014-11-05 Alphapharm Pty Ltd A dosage form containing two active pharmaceutical ingredients in different physical forms
WO2009024889A2 (en) * 2007-08-21 2009-02-26 Ranbaxy Laboratories Limited Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe
EP2844233B1 (en) * 2012-05-01 2020-05-06 Althera Life Sciences, LLC Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases
KR101910901B1 (en) * 2013-11-29 2018-10-24 한미약품 주식회사 Pharmaceutical complex formulation comprising amlodipine, losartan and rosuvastatin
KR101977785B1 (en) * 2014-06-25 2019-05-14 한미약품 주식회사 Composite formulation for oral administration comprising ezetimibe and rosuvastatin and a process for the preparation thereof
MX2017014311A (en) * 2015-06-30 2018-03-07 Hanmi Pharm Ind Co Ltd Pharmaceutical complex formulation comprising amlodipine, losartan and rosuvastatin.
CN106237334B (en) * 2016-07-29 2019-05-24 珠海赛隆药业股份有限公司（长沙）医药研发中心 A kind of angiotensin receptor antagonist and the compound of milrinone and application thereof
AU2017323593A1 (en) 2016-09-07 2019-04-11 Akamara Therapeutics, Inc. Immune memory induction by platinum based compounds
KR102569271B1 (en) * 2018-03-19 2023-08-23 한미약품 주식회사 Pharmaceutical combination preparation comprising ezetimibe and rosuvastatin

Also Published As

Publication number Publication date
EP3957303A1 (en) 2022-02-23
KR102500643B1 (en) 2023-02-16
TWI827828B (en) 2024-01-01
WO2020213868A1 (en) 2020-10-22
ZA202108268B (en) 2023-07-26
TW202103697A (en) 2021-02-01
EP3957303A4 (en) 2022-11-23
CN113747885A (en) 2021-12-03
CN113747885B (en) 2023-08-15
KR20200122517A (en) 2020-10-28
MX2021012568A (en) 2021-11-12

Similar Documents

Publication Publication Date Title
IL284835A (en) Pharmaceutical combination comprising tno155 and ribociclib
EP3709882A4 (en) Diagnostic and therapeutic splints
EP3250589A4 (en) Therapeutic and diagnostic agents
IL273339A (en) Griseofulvin compound and pharmaceutical use thereof
EP4079738A4 (en) Anticancer compound and medical use thereof
IL286079A (en) Imidazolonylquinoline compounds and therapeutic uses thereof
ZA202004982B (en) Pharmaceutical combination preparation comprising ezetimibe and rosuvastatin
GB201715194D0 (en) Compounds and their therapeutic use
PL3658122T3 (en) Pharmaceutical composition comprising sacubitril and valsartan
IL276323A (en) 4-methyldihydropyrimidinone compounds and pharmaceutical use thereof
SG11202011003TA (en) Azabenzimidazole compounds and pharmaceutical
EP4069233A4 (en) Pharmaceutical combination and use thereof
ZA202108268B (en) Pharmaceutical combination preparation comprising ezetimibe and losartan
IL282142A (en) 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament
ZA202006346B (en) Pharmaceutical preparation
PT3996688T (en) Pharmaceutical preparation
IL274177A (en) Therapeutic substances, their preparation and diagnostic procedure
GB201918541D0 (en) Therapeutic compounds and their use
GB201901989D0 (en) Pharmaceutical combinations
EP3597640A4 (en) Novel benzimidazolone compound and pharmaceutical use thereof
IL292646A (en) Pharmaceutical combination and use thereof
EP4082614A4 (en) Acylsulfamide compound and pharmaceutical use therefor
IL282157A (en) Compounds and therapeutic uses thereof
GB201718320D0 (en) Therapeutic substances and their preparation
GB201802743D0 (en) Medicament and use thereof